FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to new compounds of formula I , wherein R represents hydrogen or C1-4alkyl； W-X-Y represents O(CH2)2-4O； Ar represents an optionally substituted aromatic ring containing phenyl or naphthyl, or an optionally substituted heteroaromatic ring specified in a group consisting of quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, pyridyl, indolyl, triazolyl, benzoxazolyl, benzimidazolyl, indolinyl and benzotriazole； wherein provided Ar represents an aromatic ring, it is optionally substituted by at least one group consisting of acyl, benzoxazolyl, nitro, carboxyl, carboxyalkylC(1-3), carboxyalkylC(1-3)oxy, alkylC(1-3)oxycarbonylalkylC(1-3), alkylC(1-3)oxycarbonylalkylC(1-3)oxy, tetrazolyl, tetrazolylalkylC(1-3) and tetrazolylalkylC(1-3)oxy； provided Ar represents an optionally substituted heteroaromatic ring, it is optionally substituted by substitutes specified in a group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, trifluoromethyl, aryl, substituted aryl, halogen, amino, substituted amino, alkoxy, aryloxy, hydroxyl and nitro, and Ar is optionally additionally substituted by additional substitutes specified in a group consisting of alkyl, cycloalkyl, substituted cycloalkyl, trifluoromethyl, aryl, substituted aryl, halogen, amino, substituted amino, alkoxy, aryloxy and hydroxyl； or a pharmaceutically acceptable salt thereof. Also, the invention refers to a pharmaceutical composition having dihydrofolate reductase (DHFR) inhibitory activity on the basis of the compounds of formula I.EFFECT: there are prepared and described novel compounds which are wild-type and mutant-type Plasmodium falcipamm dihydrofolate reductase (DHFR) inhibitors and effective for treating malaria.17 cl, 16 ex, 8 tbl, 9 dwgНастоящее изобретение относится к новым соединениям формулы I где R представляет собой водород или С1-4алкил； W-X-Y представляет собой O(СН2)2-4O； Ar представляет собой необязате
